Browse > Article
http://dx.doi.org/10.5352/JLS.2011.21.10.1385

Effects of Insulin-Like Growth Factor-I on Expression of Suppressor of Cytokine Signaling-3 in C2C12 Myotube  

Kim, Hye-Jin (Department of Exercise Science, College of Health Sciences, Ewha Womans University)
Lee, Won-Jun (Department of Exercise Science, College of Health Sciences, Ewha Womans University)
Publication Information
Journal of Life Science / v.21, no.10, 2011 , pp. 1385-1392 More about this Journal
Abstract
It is well known that both insulin-like growth factor-I and suppressor of cytokine signaling-3 (SOCS-3) are known to modulate various aspects of physiology in skeletal muscle cells. Furthermore, although SOCS-3 expression is related to insulin resistance in non-skeletal muscle cells and is known to interact with insulin-like growth factor-I receptor, the effect of IGF-I on SOCS-3 gene expression in skeletal muscle cells is presently unknown. C2C12 myotubes were treated with different concentrations (0-200 ng/ml) of IGF-I or for various periods of time (3-72 hr). Immunofluorescent staining image revealed that IGF-I induced SOCS-3 protein expression in a dose-dependent manner. Western blot data also showed that SOCS-3 proteins were induced by IGF-I (200 ng/ml) in C2C12 myotubes in a time-dependent manner. The level of SOCS-3 mRNA was also significantly increased after 3hr of IGF-I (10-100 ng/ml) treatment. However, the levels of SOCS-3 mRNA were significantly decreased after 24 and 48 hr of IGF-I (10-100 ng/ml) treatment compared to the control. In conclusion, SOCS-3 protein is induced by IGF-I treatment in C2C12 skeletal muscle cells and this induction is regulated pretranslationally. The modulating effect of IGF-I on SOCS-3 expression may be an important regulator of gene expression in skeletal muscle cells.
Keywords
Insulin-like growth factor-I; suppressor of cytokine signaling-3; C2C12 myotube;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Trenerry, M. K., K. A. Carey, A. C. Ward, and D. Cameron-Smith. 2007. STAT3 signaling is activated in human skeletal muscle following acute resistance exercise. J. Appl. Physiol. 102, 1483-1489.
2 Ueki, K., T. Kondo, and C. R. Kahn. 2004. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell Biol. 24, 5434-5446.   DOI
3 Ueki, K., T. Kondo, Y. H. Tseng, and C. R. Kahn. 2004. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101, 10422-10427.   DOI
4 Wallenius, V., K. Wallenius, B. Ahrén, M. Rudling, H. Carlsten, S. L. Dickson, C. Ohlsson, and J. O. Jansson. 2002. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75-79.   DOI
5 Weigert, C., A. M. Hennige, K. Brodbeck, H. U. Häring, and E. D. Schleicher. 2005. Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am. J. Physiol. 289, E251-257.
6 Yadav, A., A. Kalita, S. Dhillon, and K. Banerjee. 2005. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J. Biol. Chem. 280, 31830-31840.   DOI
7 Yaspelkis, B. B. III., I. A. Kvasha, and T. Y. Figueroa. 2009. High-fat feeding increases insulin receptor and IRS-1 coimmunoprecipitation with SOCS-3, IKKalpha/beta phosphorylation and decreases PI-3 kinase activity in muscle. Am. J. Physiol. 296, R1709-R1715.
8 Rieusset, J., K. Bouzakri, E. Chevillotte, N. Ricard, D. Jacquet, J. P. Bastard, M. Laville, and H. Vidal. 2004. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53, 2232-2241.   DOI
9 Rui, L., M. Yuan, D. Frantz, S. Shoelson, and M. F. White. 2002. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394-42399.   DOI
10 Sadowski, C. L., T. S. Choi, M. Le, T. T. Wheeler, L. H. Wang, and H. B. Sadowski. 2001. Insulin Induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 Skeletal Muscle Cells Is Mediated by Stat5*. J. Biol. Chem. 276, 20703-20710.   DOI
11 Shi, H., I. Tzameli, C. Bjorbaek, and J. S. Flier. 2004. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J. Biol. Chem. 279, 34733-34740.   DOI
12 Spangenburg, E. E. 2005. SOCS-3 induces myoblast differentiation. J. Biol. Chem. 280, 10749-10758.   DOI
13 Spangenburg, E. E. 2006. Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression. J. Physiol. 572, 839-848.   DOI
14 Steppan, C. M., J. Wang, E. L. Whiteman, M. J. Birnbaum, and M. A. Lazer. 2005. Activation of SOCS-3 by resistin. Mol. Cell Biol. 25, 1569-1575.   DOI
15 Takeda, K. and S. Akira. 2000. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine. Growth. Factor Rev. 11, 199-207.   DOI
16 Tollet-Egnell, P., A. Flores-Morales., A. Stavréus-Evers., L. Sahlin, and G. Norstedt. 1999. Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology 140, 3693-3704.   DOI
17 Jandziszak, K., C. Suarez, E. Wasserman, R. Clark, B. Baker, F. Liu, R. Hintz, P. Saenger, and L. P Brion. 1998. Disturbances of growth hormone-insulin-like growth factor axis and response to growth hormone in acidosis. Am. J. Physiol. 275, R120-R128.
18 Jennische, E. and H. A. Hansson. 1987. Regenerating skeletal muscle cells express insulin-like growth factor I. Acta. Physiol. Scand. 130, 327-332.   DOI
19 Kim, C. H., J. H. Youn, J. Y. Park, S. K. Hong, K. S. Park, S. W. Park, K. I. Suh, and K. U. Lee. 2000. Effects of high-fat diet and exercise training on intracellular glucose metabolism in rats. Am. J. Physiol. 278, E977-E984.
20 Kakisis, J. D., C. D. Liapis, and B. E. Sumpio. 2004. Effects of cyclic strain on vascular cells. Endothelium. 11, 17-28.   DOI
21 Kraegen, E. W., D. E. James, A. B. Jenkins, D. J. Chisholm, and L. H. Storlien. 1989. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38, 1089-1093.   DOI
22 Lebrun, P. and E. Van Obberghen. 2008. SOCS proteins causing trouble in insulin action. Acta. Physiologica 192, 29-36.
23 McLellan, A. S., T. Kealey, and K. Langlands. 2006. An E box in the exon 1 promoter regulates insulin-like growth factor-I expression in differentiating muscle cells. Am. J. Physiol. 291, C300-C307.   DOI
24 Nielsen, C., L. C. Gormsen, N. Jessen, S. B. Pedersen, N. Moller, S. Lund, and J. O. Jorgensen. 2008. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J. Clin. Endocrinol. Metab. 93, 2842-2850.   DOI
25 Park, P. and P. Cohen. 2005. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm. IGF Res. 15, S13-S20.   DOI
26 Diao, Y., X. Whang, and Z. Wu. 2009. SOCS1, SOCS3, and PIAS1 promote myogenic differentiation by inhibiting the leukemia inhibitory factor-induced JAK1/STAT1/STAT3 pathway. Mol. Cell Biol. 29, 5084-5093.   DOI
27 Emanuelli, B., P. Peraldi, C. Filloux, D. Sawaka-Verhelle, D. J. Hilton, and E. Van Obberghen. 2000. SOCS-3 is an insulin- induced negative regulator of insulin signaling. J. Biol. Chem. 275, 15985-15991.   DOI
28 Galvin, C. D., O. Hardiman, and C. M. Nolan. 2003. IGF-I receptor mediates differentiation of primary cultures of mouse skeletal myoblasts. Mol. Cell Endocrinol. 200, 19-29.   DOI
29 Emanuelli, B., P. Peraldi, C. Filloux, C. Chavey, K. Freidinger, D. J. Hilton, G. S. Hotamisligil, and E. Van Obberghen. 2001. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J. Biol. Chem. 276, 47944-47949.
30 Florini, J. R., D. Z. Ewton, and S. A. Coolican. 1996. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 16, 481-517.
31 Glass, D. J. 2005. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974-1984.   DOI
32 Haddad, F., F. Zaldivar, D. M. Cooper, and G. R. Adams. 2005. IL-6-induced skeletal muscle atrophy. J. Appl. Physiol. 98, 911-917.
33 Hansen, J. A., K. Lindberg, D. J. Hilton, J. H. Nielsen, and N. Billestrup. 1999. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13, 1832-1843.   DOI
34 Hawley, J. A. and S. J. Lessard. 2008. Exercise training-induced improvements in insulin action. Acta. Physiologica 192, 127-135.
35 Holloszy, J. O. 2005. Exercise-induced increase in muscle insulin sensitivity. J. Appl. Physiol. 99, 338-343.   DOI
36 Bodell, P. W., E. Kodesh, F. Haddad, F. P. Zaldivar, D. M. Cooper, and G. R. Adams. 2009. Skeletal muscle growth in young rats is inhibited by chronic exposure to IL-6 but preserved by concurrent voluntary endurance exercise. J. Appl. Physiol. 106, 443-453.
37 Alexander, W. S. and D. J. Hilton. 2004. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503-529.   DOI
38 Auernhammer, C. J., C. Bousquet, A. Chensnokova, and S. Meled. 2000. SOCS proteins: modulators of neuroimmunoendocrine functions. Impact on corticotroph LIF signaling. Ann. N. Y. Acad. Sci. 917, 658-664.
39 Benedetti, F., T. Alonzi, A. Moretta, D. Lazzaro, P. Costa, V. Poli, A. Martini, G. Ciliberto, and E. Fattori. 1997. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99, 643-650.   DOI
40 Cacalano, N. A., D. Sanden, and J. A. Johnston. 2001. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat. Cell Biol. 3, 460-465.   DOI
41 Dey, B. R., R. W. Furlanetto, and P. Nissley. 2000. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem. Biophys. Res. Commun. 278, 38-43.   DOI